Skip to main content
OpenTrials

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

9,947 public trials 2,015 recruiting studies
Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Recruiting

A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma

NCT05650632

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Mayo Clinic Arizona /ID# 251405 Phoenix, Arizona, United States
  • Highlands Oncology Group - Springdale /ID# 267742 Springdale, Arkansas, United States
  • Rocky Mountain Cancer Centers - Aurora /ID# 268574 Aurora, Colorado, United States
  • Medical Oncology Hematology Consultants /ID# 268560 Newark, Delaware, United States
View all 46 locations
View Trial Details
Recruiting

A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21)

NCT07302347

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Merkel Cell, +20 more
Locations
  • Nagoya City University Hospital ( Site 0003) Nagoya, Aichi-ken, Japan
  • Nagoya City University Hospital ( Site 0007) Nagoya, Aichi-ken, Japan
  • Sapporo Hokuyu Hospital ( Site 0005) Sapporo, Hokkaido, Japan
  • Hyogo Prefectural Kobe Children's Hospital ( Site 0006) Kobe, Hyōgo, Japan
View Trial Details
Recruiting

A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)

NCT07073547

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Research Site Phoenix, Arizona, United States
  • Research Site Duarte, California, United States
  • Research Site Denver, Colorado, United States
  • Research Site Tampa, Florida, United States
View all 13 locations
View Trial Details
Recruiting

Teclistamab-Daratumumab in AL Amyloidosis

NCT07110844

Conditions
Amyloid Light-chain Amyloidosis, Amyloidosis, Immune System Diseases, +10 more
Locations
  • Boston Medical Center Boston, Massachusetts, United States
  • Columbia University Irving Medical Center New York, United States
  • Medical College of Wisconsin Milwaukee, Wisconsin, United States
View Trial Details
Recruiting

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma

NCT05169515

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +7 more
Locations
  • UCSF/Hematology, Blood & Marrow Transplant, And Cellular Therapy (HBC) Program San Francisco, California, United States
  • University of Colorado Aurora, Colorado, United States
  • Moffitt Cancer Center Tampa, Florida, United States
  • The University of Chicago Chicago, Illinois, United States
View all 26 locations
View Trial Details
Recruiting

DALY II USA/ MB-CART2019.1 for DLBCL

NCT04792489

Conditions
Central Nervous System Lymphoma, Central Nervous System Neoplasms, Hemic and Lymphatic Diseases, +22 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • Banner MD Anderson Cancer Center Gilbert, Arizona, United States
  • Mayo Clinic Phoenix, Arizona, United States
  • UC San Diego Health La Jolla, California, United States
View all 32 locations
View Trial Details
Recruiting

A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)

NCT05579132

Conditions
Acute Lymphoblastic Leukemia, Hematologic Diseases, Hemic and Lymphatic Diseases, +9 more
Locations
  • The Second Affiliated Hospital of Third Military Medical University ( Site 0008) Chongqing, Chongqing Municipality, China
  • Southern Medical University Nanfang Hospital ( Site 0004) Guangzhou, Guangdong, China
  • The Second Hospital of Hebei Medical University ( Site 0003) Shijiazhuang, Hebei, China
  • The First Hospital of Harbin ( Site 0005) Harbin, Heilongjiang, China
View Trial Details

Related conditions